Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Hansa Biopharma completes the AMNOG reimbursement process for Idefirix[®] in Germany · Hansa and National Association of Statutory Health Insurance Funds (GKV-SV) agree on reimbursement price · German hospitals can receive extra funding for the final reimbursement price based on a positive NUB status 1 decision Lund, Sweden, March 15, 2022. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces having reached an agreement on the reimbursement for Idefirix in Germany with the National Association of